BIO-TECHNE Corp (TECH) bonds
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value
$72.80−0.02 (-0.03%)
Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%
Debt
Borrowings on the balance sheet, Sep 30, 2026
Bio-Techne reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Bio-Techne's 10-K for the period ended Aug 31, 2022
Bio-Techne's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Amended Credit Agreement | $1.00B |
See a number that looks wrong?